If you are losing weight consistently and managing side effects well at a lower dose, there is no clinical reason to increase further
Annual Review of Physiology, 37, 379-408
We will further look into this and explore how we can help patients with addiction, potentially with GLP-1, Lange said, also adding that it has to be addressed in a scientific, and obviously also from a regulatory perspective, very rigorous way so we can really see the potential impact of GLP-1 in that space. However, in response to questions from Biospace, a Novo spokesperson said that Lange was referring to the already ongoing work studying semaglutide on liver damage and alcohol use in its phase 2 trial, and that the company has no plans to study the drug in broader addiction indications
If your appetite is very low, skipping meals all day may seem easy at first, but it can leave you low on protein, fiber, vitamins, minerals, and energy